Obesity Pipeline Expands with Over 100 Therapies from 80+ Companies

The global obesity drug development pipeline comprises over 100 therapies from more than 80 companies, according to an analysis covering clinical trials, mechanisms of action, and development status.

Anticipated developments include major regulatory milestones. In April 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Eli Lilly's oral weight-loss treatment, orforglipron. This GLP-1 class drug mimics a natural hormone that regulates appetite and promotes fullness, becoming the second daily pill available for obesity management.

Additionally, Rhythm Pharmaceuticals received expanded FDA approval in March 2026 for setmelanotide (Imcivree) in acquired hypothalamic obesity, marking the first treatment specifically for this condition. The launch of Novo Nordisk's first oral GLP-1 pill for obesity in early 2026 is also expected to broaden patient access.

Other notable advancements include Arrowhead Pharmaceuticals administering the first doses of its RNAi therapy ARO-ALK7 in June 2025 and Corxel Pharmaceuticals initiating a Phase II trial for its oral GLP-1 receptor agonist CX11 in April 2025. Zealand Pharma completed enrollment for its Phase IIb trial of petrelintide in March 2025.

A recent survey of healthcare professionals indicated a growing focus on multi-indication cardiometabolic research for obesity. The market sees significant investment from major pharmaceutical players including Merck, Bayer, GlaxoSmithKline, Bristol-Myers Squibb, and Roche.